Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration : Episode 2
Overview of Cytokine Release Syndrome (CRS) and Its Management
Sagar Lonial, MD, and Ellen Marin, PA-C, discuss cytokine release syndrome (CRS) and the strategy to manage CRS in their clinic.
Video Player is loading.
EP: 1.Overview of Relapsed or Refractory Multiple Myeloma (RRMM)
Now Viewing
EP: 2.Overview of Cytokine Release Syndrome (CRS) and Its Management
EP: 3.Background Information and Study Method
EP: 4.Patient Demographics and Study Results
EP: 5.Study Conclusions and Its Implications
EP: 6.Study Impact and Key Takeaways
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Related Content
